ReviewBioMedicine2025
Unveiling role of oncogenic signalling pathways in complicating breast cancer.
Review in BioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Netrin-1 Mediates the Suppression of Osteolytic Bone Metastasis in Breast Cancer by Ugonin L.International journal of biological sciences · 2026Article
- Decyl caffeate inhibits the proliferation of human triple negative breast cancer cells.BioMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneous nature of breast cancer has significantly affected the overall survival, disease free survival and progression free survival amongst the diseased individuals. Metastasis of cancerous cells to distant sites including bone, lungs, liver, lymph node and others have further exhilarated the adverse effects. However, ER, PR and HER-2 are responsible for normal physiological development of women but in altered conditions they may act as initiator or progressor and so far 5 subtypes of disease have been identified. Alteration of pro-survival, pro-proliferative and anti-apoptotic pathways including JAK/STAT, MAPK, PI3K/AkT/mTOR, NF-κB, BCL2 and several others have induced oncogenic events including epithelial-mesenchymal transition, intra-vasation, extra-vasation and many more. Although several US-FDA approved drugs are available in market to target above mentioned signalling pathways but issues of resistance, side effects have restricted their efficacy. The present review article aims to highlight diverse molecular subtypes and the signalling pathways involved in complicating the disease along with the US-FDA approved drugs to target them. Potential herbal medicine to target the disease have also been emphasized that can be used either as mono-therapeutic approach or in combination with conventional therapeutic regimens to target breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.